A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
Obesity and insulin resistance are known to promote tumor growth and accelerate the mortality of patients with cancer. Evexomostat is a novel antiangiogenic and antimetastatic drug candidate which also has insulin-sensitizing and antiobesity properties that is being developed for use in combination with standard-of-care therapies for obese patients with cancer.
Authors
- Alfred Anderson-Villaluz
- Bradley J. Carver (ORCID: https://orcid.org/0009-0008-0081-4764)
- Benjamin A. Mayes (ORCID: https://orcid.org/0009-0008-8762-6650)
- Alain C. Mita
- David J. Turnquist (ORCID: https://orcid.org/0009-0000-5423-3174)
- Pierre J. Dufour (ORCID: https://orcid.org/0009-0005-8476-1679)
- Peter Cornelius (ORCID: https://orcid.org/0009-0000-9448-3792)
- James M. Shanahan (ORCID: https://orcid.org/0009-0006-1115-1519)
- John S. Petersen (ORCID: https://orcid.org/0009-0007-6006-8700)
- David J. Browning
- Monica Mita
Institutions
- Cedars-Sinai Medical Center (US)
- Hoag Memorial Hospital Presbyterian (US)
- University of Massachusetts Lowell (US)
- Ansys (United States) (US)
- Mission Bio (United States) (US)
- SynDevRx (United States) (US)
- Anthem (United States) (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0627
- Citations
- 3
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42